Date: 01.06.2026
Financial Performance Summary
Quarterly Performance (Q4 FY26 vs Q4 FY25)
| Metric | Q4 FY26 | Q4 FY25 | YoY Change |
| Revenue from Operations (₹ crores) | 35.1 | 35.1 | 0.2% |
| EBITDA (₹ crores) | 4.0 | 2.8 | 39.7% |
| EBITDA Margin | 11.3% | 8.1% | 320 bps improvement |
| Profit After Tax (₹ crores) | 0.8 | 1.2 | -28.2% |
| PAT Margin | 2.4% | 3.3% | -95 bps |
Annual Performance (FY26 vs FY25)
| Metric | FY26 | FY25 | YoY Change |
| Revenue from Operations (₹ crores) | 126.4 | 133.9 | -5.6% |
| EBITDA (₹ crores) | 10.0 | 10.6 | -5.6% |
| EBITDA Margin | 7.9% | 7.9% | 0 bps |
| Profit After Tax (₹ crores) | 1.0 | 4.0 | -74.1% |
| PAT Margin | 0.8% | 3.0% | -215 bps |
Performance Drivers and Highlights
Q4 FY26 Performance Analysis
Revenue from operations remained largely stable at ₹35.1 crore, reflecting the company's resilient business performance despite ongoing global disruptions. EBITDA showed significant improvement, growing 39.7% YoY to ₹4.0 crore, with EBITDA margins expanding by 320 basis points to 11.3%. This improvement was supported by operational efficiencies and improved profitability. However, Profit After Tax declined by 28.2% YoY to ₹0.8 crore, with PAT margins contracting by 95 basis points to 2.4%.
FY26 Performance Analysis
Full-year revenue declined by 5.6% YoY to ₹126.4 crore. EBITDA also declined by 5.6% YoY to approximately ₹10.0 crore, though the company maintained a stable EBITDA margin of 7.9%, in line with FY25. Profit After Tax saw a significant decline of 74.1% YoY to ₹1.0 crore, translating to a PAT margin of 0.8% compared to 3.0% in FY25.
The decline in PAT was primarily attributable to investments made in the two subsidiaries, Vital Synthesis and Vital Alkoxides.
Operational and Strategic Highlights
Subsidiaries Performance
- Vital Synthesis Limited: Commenced commercial operations in Q3 FY26 and witnessed encouraging customer response. The company expects gradual scale-up through increasing product acceptance and customer engagement.
- Vital Alkoxides Private Limited: Delivered strong business momentum during FY26, achieving approximately 63% YoY revenue growth.
During FY26, the company's subsidiaries continued to strengthen the group's long-term growth platform and specialty chemicals portfolio. Management remains optimistic about the future growth prospects and strategic contribution of both subsidiaries.
Management Commentary
Mr. Vipul Bhatt, Chairman and Managing Director, commented: "In FY26, Vital Chemtech focused on strengthening its business foundation through strategic investments, operational improvements, and expansion across specialty chemical segments. Despite challenging global market conditions, the company demonstrated resilience with stable revenue performance and improved operational efficiencies during Q4 FY26."
"During the year, the company continued to invest in its subsidiaries, Vital Synthesis Limited and Vital Alkoxides Private Limited, with a long-term vision of expanding its presence in high-growth specialty chemical markets. While these investments impacted short-term profitability, they are expected to strengthen the group's growth platform, diversification strategy, and future earnings potential."
"The company remains focused on improving capacity utilization, optimizing product mix, strengthening customer relationships, and expanding its portfolio of value-added specialty chemical products. Backed by its integrated manufacturing facility at Dahej and growing capabilities across the group, Vital Chemtech remains well-positioned to capitalize on long-term opportunities across domestic and export markets."
Company Background
Vital Chemtech Limited is an Indian chemical manufacturing company headquartered in Ahmedabad, specializing in producing key phosphorus derivative products and diverse range of specialty chemicals that serve as essential raw materials for several high-growth industries. The company operates through a fully automated and integrated manufacturing complex located at Dahej, Gujarat, with a cumulative installed capacity of 33,192 MT.